Tilray Brands, Inc. (TLRY)
Automate Your Wheel Strategy on TLRY
With Tiblio's Option Bot, you can configure your own wheel strategy including TLRY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TLRY
- Rev/Share 9.8033
- Book/Share 0.0
- PB 0.0
- Debt/Equity 0.0
- CurrentRatio 0.0
- ROIC 0.0
- MktCap 1013034913.0
- FreeCF/Share -0.5797
- PFCF -15.8384
- PE -0.3456
- Debt/Assets 0.0
- DivYield 0
- ROE -1.5511
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Weekly Jobless Claims Come in Muted
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Neutral
Weekly Jobless Claims Come in Muted.
Read More
Tilray Q2: High Hopes or Harsh Reality?
Published: January 06, 2026 by: Benzinga
Sentiment: Neutral
As Canadian cannabis king Tilray Brands, Inc. (NASDAQ: TLRY) prepares to report its fiscal Q2 2026 results on Thursday, the company stands at a crossroads.
Read More
Tilray Brands Readies for Q2 Earnings: Here's What You Should Know
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
TLRY's faces margin pressure in cannabis and beverages, but management sees a beverage turnaround and wellness strength cushioning quarterly results.
Read More
How Long Will the Cannabis Stock Rally Last?
Published: January 01, 2026 by: The Motley Fool
Sentiment: Positive
Cannabis stocks have had significant momentum due to positive regulatory changes in the U.S. However, this momentum is likely to be relatively short-lived. These 10 Stocks Could Mint the Next Wave of Millionaires ›
Read More
Riding the Marijuana Reclassification Wave: 3 Stocks to Watch in 2026
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Marijuana's potential move to Schedule III could reshape cannabis economics, putting CRON, VFF and TLRY in focus for 2026 investors.
Read More
The 2026 Cannabis Wildcard: How Tax Reform Could Reset Stock Valuations
Published: December 30, 2025 by: MarketBeat
Sentiment: Neutral
On Dec. 18, 2025, President Trump signed a pivotal Executive Order directing the Attorney General to expedite the rescheduling of cannabis. By all traditional metrics, this political victory should have sparked a sustained rally.
Read More
3 Marijuana Stocks To Watch In 2026
Published: December 26, 2025 by: MarijuanaStocks
Sentiment: Positive
The cannabis industry is entering another critical growth phase, positioning 2026 as a potentially pivotal year. Particularly for long-term investors looking to make a profit with marijuana stocks. After years of regulatory uncertainty, capital constraints, and volatile price action, relief is being shown. The legal cannabis market is showing clear signs of structural improvement driven by policy reform, consolidation, and expanding global demand.
Read More
3 Top Marijuana Stocks After Cannabis Gets Rescheduled
Published: December 22, 2025 by: MarijuanaStocks
Sentiment: Positive
Donald Trump's recent executive order moving cannabis off Schedule I marks a pivotal moment for the U.S. cannabis sector. While the order does not legalize marijuana at the federal level, rescheduling fundamentally changes how the plant is viewed under federal law. With meaningful implications for operators, investors, and public markets. For the cannabis industry, the most immediate impact is financial. A shift to Schedule III would effectively eradicate IRS Section 280E. This is a law that currently prevents cannabis businesses from deducting standard operating expenses.
Read More
Tilray Brands to Announce Second Quarter Fiscal Year 2026 Financial Results on January 8, 2026
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and LEAMINGTON, Ontario, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage and wellness industries, today announced that the Company will release its financial results for the second fiscal quarter which ended November 30, 2025, after the financial markets close on Thursday, January 8, 2026.
Read More
3 Best Cannabis Stocks: Will They Fly High Again Post Trump Schedule III?
Published: December 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Cannabis stocks sold off this week following President Trump's Executive Order directing marijuana's reclassification to Schedule III for increased medical and cannabidiol research. The sharp selloff highlights how fragile sentiment in cannabis stock remains, even amid policy progress. Further volatility is possible if regulatory implementation drags on or if broader market risk appetite weakens.
Read More
Trump signs executive order to reschedule cannabis. Here's what's next
Published: December 19, 2025 by: CNBC Television
Sentiment: Positive
Trump's executive order shifts cannabis from Schedule I to Schedule III, and launches a Medicare pilot program for CBD products. Brandon Gomez unpacks what's next, the hurdles ahead and what shifted the President's stance on the drug.
Read More
Trump just legalized marijuana nationwide — here's why potheads are rejoicing
Published: December 19, 2025 by: New York Post
Sentiment: Positive
As On The Money has been reporting since April, our famously drug-and-drink-averse president has been inching ever closer to making marijuana significantly less criminal in the eyes of the federal government.
Read More
Trump Orders Marijuana Reclassification: What It Means for the Sector
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Trump's executive order to move marijuana to Schedule III could reshape cannabis regulation and taxes, lifting sentiment around cannabis stocks.
Read More
Trump sparks market shock with MAJOR marijuana move
Published: December 19, 2025 by: Fox Business
Sentiment: Negative
Rep. Greg Steube, R-Fla., joins ‘Mornings with Maria' to discuss cutting healthcare costs, the fight over Obamacare subsidies and shutdown risks, President Donald Trump's marijuana order and the GOP's push to sell unused federal buildings.
Read More
Trump signs executive order to reschedule marijuana, expand access to CBD products
Published: December 18, 2025 by: Proactive Investors
Sentiment: Positive
President Donald Trump on Thursday signed an executive order directing the federal government to move marijuana from Schedule I to Schedule III, potentially easing regulatory and financial constraints for cannabis companies while keeping recreational use illegal under federal law. The order instructs the attorney general to expedite the ongoing process of rescheduling marijuana, which is currently classified alongside heroin and LSD as a Schedule I drug — considered to have a high potential for abuse and no accepted medical use.
Read More
President Trump signs executive order to reclassify marijuana, easing federal restrictions
Published: December 18, 2025 by: CNBC Television
Sentiment: Positive
President Trump signs an executive order to reclassify marijuana to a Schedule III classification, easing federal restrictions.
Read More
TLRY Soars on Marijuana Reclassification Hopes, Burning Question Centers on Profits
Published: December 18, 2025 by: Schwab Network
Sentiment: Positive
Tilray Brands (TLRY) has been one of the top stocks gaining momentum in the cannabis space as President Trump is expected to sign an executive order reclassifying cannabis. George Tsilis says that paving a clean path for legalization does not equate to more demand, thus more revenue.
Read More
Trump Signs Order Easing Federal Restrictions on Marijuana
Published: December 18, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
President Donald Trump signs an executive order directing his administration to move cannabis into a less restrictive federal category. Sign up for the Washington Edition newsletter to find out how the worlds of money and politics intersect in the US capital: https://bloom.bg/3KkEimO -------- More on Bloomberg Television and Markets Like this video?
Read More
Tilray Accelerates U.S. Medical Cannabis Expansion After Landmark Federal Rescheduling: Launches Tilray Medical USA to Lead Nationwide Medical Cannabis Innovation and Growth
Published: December 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Global Cannabis Leader Poised for Major U.S. Market Entry, Signaling New Era for Healthcare Global Cannabis Leader Poised for Major U.S. Market Entry, Signaling New Era for Healthcare
Read More
Trump signs executive order easing federal restrictions on marijuana
Published: December 18, 2025 by: Business Insider
Sentiment: Positive
Trump signed an executive order that will reclassify marijuana as a less harmful drug. The order is aimed at making it easier to research the drug.
Read More
Trump signs executive order reclassifying pot, opening door to broader access
Published: December 18, 2025 by: CNBC
Sentiment: Positive
President Donald Trump signed an executive order Thursday reclassifying marijuana as a Schedule III substance with looser restrictions.
Read More
Trump moves to ease cannabis restrictions - what does it mean for consumers?
Published: December 18, 2025 by: Reuters
Sentiment: Positive
U.S. President Donald Trump said he will direct the U.S. Department of Justice to reclassify cannabis as a less dangerous drug. Here's a look at what that would mean for people shopping at dispensaries across the country.
Read More
Cannabis stocks rise ahead of potential Trump order to ease marijuana restrictions
Published: December 18, 2025 by: Reuters
Sentiment: Positive
Shares of cannabis firms rose in premarket trading on Thursday, driven by expectations that U.S. President Donald Trump will sign an executive order easing federal regulations on marijuana.
Read More
Pot stocks pop on Schedule 3 hopes: Tilray Brands, Trulieve Cannabis, Cresco Labs: How high will they go?
Published: December 17, 2025 by: Fast Company
Sentiment: Positive
Shares of publicly traded companies operating in the cannabis space continue to perform strongly as the Trump administration considers reclassifying marijuana.
Read More
Best Canadian Cannabis Stocks to Watch This Week for Traders and Investors
Published: December 16, 2025 by: MarijuanaStocks
Sentiment: Positive
Canadian cannabis stocks remain in focus this week as sector sentiment continues improving. Several Canadian operators maintain meaningful exposure to the U.S. market through brands and partnerships. Meanwhile, the U.S. cannabis industry continues expanding despite regulatory delays. Total U.S. cannabis sales now exceed $32 billion annually. Importantly, analysts project the market could surpass $50 billion by 2030. That growth outlook keeps Canadian operators relevant for global investors. Recently, renewed federal reform discussions returned to headlines. Cannabis rescheduling remains under active government review. Additionally, lawmakers continue debating banking access and tax reform measures. While timing remains uncertain, momentum has improved compared …
Read More
The Rally for Cannabis Stocks Grinds to a Halt Amid Uncertainty About Trump Order
Published: December 15, 2025 by: Investopedia
Sentiment: Negative
Weed stocks aren't flying so high anymore.
Read More
Tilray Brands, Inc. (TLRY) Crossed Above the 20-Day Moving Average: What That Means for Investors
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Tilray Brands, Inc. (TLRY) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TLRY crossed above the 20-day moving average, suggesting a short-term bullish trend.
Read More
Tilray Brands, Inc. (TLRY) Just Overtook the 200-Day Moving Average
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Tilray Brands, Inc. (TLRY) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TLRY crossed above the 200-day moving average, suggesting a long-term bullish trend.
Read More
Tilray Brands Soars on Reports of Likely US Marijuana Reclassification
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
TLRY surges 44.1% on reports that Trump may reclassify marijuana, sparking hopes for eased federal rules and renewed investor enthusiasm.
Read More
Trump Expected to Label Pot a Less Dangerous Drug
Published: December 12, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
President Donald Trump is expected have his administration classify marijuana as a less dangerous drug, according to people familiar with the matter. This has been good news for pot stocks.
Read More
About Tilray Brands, Inc. (TLRY)
- IPO Date 2018-07-19
- Website https://www.tilray.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Irwin David Simon
- Employees 2650